Literature DB >> 34280192

Factors affecting IGF-I level and correlation with growth response during growth hormone treatment in LG Growth Study.

Ji Hyun Kim1, Su Jin Kim2, Jieun Lee3, Choong Ho Shin4, Ji-Young Seo5.   

Abstract

Growth hormone treatment strategies to achieve the goal include the titration of GH doses according to serum insulin-like growth factor I (IGF-I) concentrations. However, IGF-I levels do not always correlate well with the growth response. This study aims to identify the factors affecting the IGF-I concentration and identify the relationship between IGF-I and the treatment response. The data of prepubertal children treated with recombinant human GH for more than one year were obtained from the LG Growth Study (LGS) Database. This study includes patients with idiopathic growth hormone deficiency (IGHD), organic growth hormone deficiency (OGHD), or Turner syndrome (TS) or small for gestational age (SGA). Among 2,021 participants registered in LGS, 366 subjects were selected, 252 had IGHD, 16 had OGHD, 31 had TS, and 67 were SGA. In the IGHD and SGA groups, IGF-I levels had a positive correlation with weight SDS. There was no significant relationship between the pre-treatment IGF-I level and growth response. However, in the IGHD group, the growth response was significantly higher when the change in the IGF-I SDS value was 1 or more (p = 0.0013). Therefore, IGF-I concentrations should be used as an indicator to monitor the treatment compliance rather than for efficacy determination in Korean children of short stature with GH treatment.

Entities:  

Year:  2021        PMID: 34280192     DOI: 10.1371/journal.pone.0252283

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  37 in total

Review 1.  Molecular mechanisms of IGF-I deficiency.

Authors:  Ron G Rosenfeld
Journal:  Horm Res       Date:  2006-03-02

2.  Reference values for serum levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in Korean children and adolescents.

Authors:  Sei Eun Hyun; Byung Churl Lee; Byung Kyu Suh; So Chung Chung; Cheol Woo Ko; Heung Sik Kim; Kee Hyoung Lee; Sei Won Yang; Choong Ho Shin; Jin Soon Hwang; Duk Hee Kim; Baek Keun Lim; Jong Duck Kim; Han-Wook Yoo; Hye Soon Kim; Woo Yeong Chung; Mi Jung Park; Young Jong Woo; Chan Jong Kim; Dae-Yeol Lee; Eun Young Kim; Jin Ho Choi; Heon Seok Han; Il Tae Hwang; Ho-Seong Kim
Journal:  Clin Biochem       Date:  2011-10-12       Impact factor: 3.281

3.  Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth.

Authors:  V Tillmann; L Patel; M S Gill; A J Whatmore; D A Price; M S Kibirige; J K Wales; P E Clayton
Journal:  Clin Endocrinol (Oxf)       Date:  2000-09       Impact factor: 3.478

4.  Relevance of IGF-I, IGFBP-3, and IGFBP-2 measurements during GH treatment of GH-deficient and non-GH-deficient children and adolescents.

Authors:  M B Ranke; R Schweizer; M W Elmlinger; K Weber; G Binder; C P Schwarze; H A Wollmann
Journal:  Horm Res       Date:  2001

5.  The insulin-like growth factor-I response to growth hormone is increased in prepubertal children with obesity and tall stature.

Authors:  Natacha Bouhours-Nouet; Frédérique Gatelais; Florence Boux de Casson; Stéphanie Rouleau; Régis Coutant
Journal:  J Clin Endocrinol Metab       Date:  2006-11-07       Impact factor: 5.958

Review 6.  Genetic variations and normal fetal growth.

Authors:  D B Dunger; C J Petry; K K Ong
Journal:  Horm Res       Date:  2006-04-10

Review 7.  Guidelines for the use of growth hormone in children with short stature. A report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society.

Authors: 
Journal:  J Pediatr       Date:  1995-12       Impact factor: 4.406

8.  Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index.

Authors:  A Juul; P Bang; N T Hertel; K Main; P Dalgaard; K Jørgensen; J Müller; K Hall; N E Skakkebaek
Journal:  J Clin Endocrinol Metab       Date:  1994-03       Impact factor: 5.958

9.  Plasma levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of childhood growth hormone deficiency.

Authors:  B Rikken; J van Doorn; A Ringeling; J L Van den Brande; G Massa; J M Wit
Journal:  Horm Res       Date:  1998-09

10.  Long-term safety and effectiveness of growth hormone therapy in Korean children with growth disorders: 5-year results of LG Growth Study.

Authors:  Young-Jun Rhie; Jae-Ho Yoo; Jin-Ho Choi; Hyun-Wook Chae; Jae Hyun Kim; Sochung Chung; Il Tae Hwang; Choong Ho Shin; Eun Young Kim; Ho-Seong Kim
Journal:  PLoS One       Date:  2019-05-16       Impact factor: 3.240

View more
  2 in total

1.  Effects of high-dose recombinant human growth hormone treatment on IGF-1 and IGFBP-3 levels in idiopathic dwarfism patients.

Authors:  Bin Wu; Honghua Lin; Jian Gao; Juan Sun; Meng Zhao
Journal:  Pak J Med Sci       Date:  2022 Mar-Apr       Impact factor: 2.340

2.  The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency.

Authors:  Yan Liang; Cai Zhang; Haiyan Wei; Hongwei Du; Gaixiu Zhang; Yu Yang; Hua Zhang; Haihong Gong; Pin Li; Fuying Song; Zhuangjian Xu; Ruoyi He; Weidong Zhou; Heng Zheng; Li Sun; Xiaoping Luo
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-11       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.